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Introduction
Research suggests that selenium may influence the beha-
vior of the cancer risk in two ways. As an antioxidant,
selenium helps to protect the body against free radicals.
Selenium may also prevent or slow tumor growth, as
some breakdown products of selenium can inhibit
tumor growth by enhancing immune cell activity and
inhibition of tumor blood vessel development.
Aim
The aim of this study was to determine the level of sele-
nium in blood serum as a potential marker of risk for
cancers of the colon, stomach or pancreas.
Material and methods
The research material was a total of 94 samples of blood
serum from people with cancer, diagnosed and confirmed
in one of the organs: colon (55 cases), pancreas (30 cases)
or stomach (9 cases) and 94 samples of blood serum
derived from healthy individuals which paired control
group. The criteria adopted for pairing included: gender,
year of birth (+/- 3 years), history of the occurrence of
cancers in the family among first degree relatives and
smoking status expressed in pack-years.
Selenium concentration in blood plasma was deter-
mined using graphite furnace atomic absorption spectro-
metry (GFAAS). The measurement accuracy was +/- 5%
µg Se/l.
Results
Association between Se concentration and frequency of
cancers in quartiles are presented in table 1. Statistical
analyses are summarized in table 2.
Conclusions
The obtained results suggest that low levels of selenium
in the body may correlate with an increased risk of pan-
creatic cancer, colon or stomach, and thus constitute
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Table 1 Association between Se plasma concentration and risk of cancers analyzed.
Cancer site Quartile Se concentration range (µg/l) Cases [% - no]
Pancreas I 25,69-50,09 100% (15/15)
II 50,72-65,58 60% (9/15)
III 66,34-73,30 40% (6/15)
IV 74,07-113,89 - (0/15)
Colorectal and stomach I 15,92-55,25 87,5% (28/32)
II 56,08-67,05 59,37% (19/32)
III 67,22-75,96 25% (8/32)
IV 76,45-103,36 28,13% (9/32)
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one of the markers of risk for cancers of such sites.
Research requires the extension to a larger number of
samples including tumor size, and performance analysis
for selenoprotein genes.
Prospective studies can elucidate:
a) the use of selenium measurements as markers of
risk of above cancers;
b) possibility of lowering risk of the cancers of the
colon, pancreas and stomach by supplementation of diet
with selenium.
Author details
1Department of Genetics and Pathology, Pomeranian Medical University in
Szczecin, Poland. 2Laboratory of Endoscopy, Division of Health Care Ministry
of Internal Affairs and Administration in Szczecin, Poland. 3Department of
General and Oncological Surgery, Pomeranian Medical University, Szczecin,
Poland.
Published: 20 April 2012
doi:10.1186/1897-4287-10-S3-A13
Cite this article as: Lener et al.: Selenium and the risk of cancers of the
colon, pancreas and stomach. Hereditary Cancer in Clinical Practice 2012
10(Suppl 3):A13.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tab.2 Results of statistical analyses of cancer site depending on Se concentration.
Cancer site Quartiles compared Se concentration range (µg/l) Cases/controls in compared groups Fisher’s exact test
P OR CI
Pancreas I vs II 25,69-50,09 vs 50,72-65,58 15/0 vs 9/6 0,017 21,2 1,07-421,11
I vs III 25,69-50,09 vs 66,34-73,30 15/0 vs 6/9 0,0007 45,3 2,2-899,53
I vs IV 25,69-50,09 vs 74,07-113,89 15/0 vs 0/15 <0,0001 961 7,9-51,617
Colorectal and stomach I vs II 15,92-55,25 vs 56,08-67,05 (5)*28/4 vs (3)*19/13 0,0219 4,79 1,35-16,94
I vs III 15,92-55,25 vs 67,22-75,96 (5)*28/4 vs (0)*8/24 <0,0001 21 5,6-78,5
I vs IV 15,92-55,25 vs 76,45-103,36 (5)*28/4 vs (1)*9/23 <0,0001 17,9 4,8-65,7
*stomach cancer cases
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